Agenus Inc.

MarketBeat’s coverage summarizes the current consensus “Hold” recommendation on Agenus, with three analysts following the stock, an average price target of 30.00 (implying roughly 491% upside from the recent price), and discussion of recent earnings misses alongside profitability metrics such as trailing EPS, P/E ratios, and margins. The piece frames Agenus as a speculative biotech with significant upside potential but highlights execution and financial risks, reinforcing a neutral stance despite the high target price.

Macroaxis presents a quantitative and narrative valuation model suggesting Agenus is undervalued, with an estimated “Real Value” of 5.24 versus a higher target price of 12.33, while detailing intrinsic value, technical drivers, and diagnostics such as debt ratios, volatility measures, and Piotroski/Beneish scores. The report stresses that Agenus has frail financial health, negative margins, high probability of financial distress, and extreme return on equity figures, positioning the stock as a high-risk, potentially mispriced equity where downside financial risk tempers the valuation upside.

Flash’s research report profiles Agenus as a clinical‑stage immuno‑oncology company centered on its BOT/BAL antibody combination, emphasizing best‑in‑class early survival data in refractory microsatellite‑stable colorectal cancer and an “explosive” growth outlook entirely dependent on the pivotal BATTMAN Phase 3 trial. It outlines scenario analyses (high, base, and downside cases), underscores severe balance‑sheet weakness, negative equity, and the critical importance of closing the Zydus transaction to fund operations, concluding that Agenus is a textbook high‑risk, high‑reward equity whose outcome is highly sensitive to both clinical and financing milestones.